Chimeric Therapeutics Ltd
CHM’s strategy is to develop a highly prospective portfolio of clinical-stage cell therapy products including CAR T and NK therapies, developed at the world’s leading medical institutions, and to drive these drugs successfully through clinical development for the benefit of cancer patients globally.
Phone (including country code)
The choice you make above will help our platform display content that is best suited to you
Welcome to the new Wholesale Investor platform. Please use your existing log in details to access the site. Alternatively feel free to use the "Login with LinkedIn" or "Sign in with Google" buttons.
Enter your email to reset your password.